VCM
CAPR icon

Versant Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Versant Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-156
Closed -$4.74K – 2766
2026
Q1 		$4.74K Buy
+156
New +$4.16K ﹤0.01% 2399

Other funds holding CAPR

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return

Versant Capital Management's CAPR Position: Q2 2026 in Review

Versant Capital Management sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 156 shares — an estimated $4.74K sold.

Versant Capital Management first reported a position in CAPR in Q1 2026 and held it in 1 quarter. The position peaked at $4.74K in Q1 2026. 11 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Versant Capital Management reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 156 Capricor Therapeutics shares in Q2 2026, an estimated $4.74K.
  • Versant Capital Management first reported a position in Capricor Therapeutics in Q1 2026 and held it in 1 quarter.
  • Versant Capital Management's Capricor Therapeutics position peaked at $4.74K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.